Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
6 lessons
9mUBT251 is a once-weekly GLP-1, GIP and glucagon receptor agonist in development in China. Two phase 2 trials published in Cell Metabolism in October 2026. Here is what they measured, how to read the numbers, and why they can't be ranked against retatrutide.
14mOn October 28, 2026, HHS said it will not take enforcement action against qualifying 503A compounding for six peptides while FDA rulemaking continues. That is not FDA approval and not a bulks-list addition. This explainer maps the policy in plain language.
7mPatients ask about BPC-157 after extractions and implants. The dental literature is one rat periodontitis model, one rat oral-injury model, and three uncontrolled human cases. Here is each one.
9mNo drug containing GHK-Cu is FDA approved. Topical copper peptides are cosmetics, non-injectable GHK-Cu is still under FDA evaluation, and GHK-Cu is not on the October 2026 HHS peptide list.
10mEpitalon is a lab-made four-amino-acid peptide based on a pineal gland extract. It lengthens telomeres in cell studies, but human evidence is small and old. It is not FDA approved, and since October 2026 it is one of six peptides in an HHS compounding policy.
9mMOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It has strong mouse data, one recruiting placebo-controlled human trial and no FDA approval. In October 2026 HHS added it to an interim compounding policy.
Also available at /blog for legacy links.